Cerulea Clinical Trials

Science and Research

COAST

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD).

Overview

A 2-year Phase 3, multicentre, randomised, parallel-group, sham-controlled, double-masked study.

Primary efficacy will be determined at Week 52.

For further information about this study please contact the Cerulea on +61 3 8638 5300 or email info@ceruleaclinicaltrials.org.au

  • Principal Investigator
Dr Thanh Nguyen

Learn more

View this study on ClinicalTrials.gov

See the ClinicalTrials.gov database listing for more detailed information about this study.